Vitamin K 100 mcg by Solaray — Ingredients, Evidence & Safety

🟢 100/100

This product looks safe

No ingredients exceed tolerable upper intake levels
100% of ingredients have research evidence

A Label Compliance Grade

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size

100 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin K

100 mcg (83% DV)

✅ Within RDA (0.8× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)

RDA 0.12mg This product: 0.1mg

Other Ingredients

Cellulose Stearic Acid Silica Magnesium Stearate

Label Claims — Verification

❓ Nutrient

❓ All Other

❓ Structure/Function

All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years) Dairy Free

Product Information

📋 Directions for Use

Directions: Use only as directed. Take 1 tablet daily with a meal or glass of water.

⚠️ Warnings & Precautions

Warning: Do not use if safety seal is broken or missing. Keep your licensed health care practitioner informed when using this product.

Keep out of reach of children.

🧪 Formulation Notes

+ Bone Support + Blood Support

Vegan

Discussion: Vitamin K-1, also known as phylloquinone, is present mostly in dark, leafy green vegetables. Vitamin K helps with normal, healthy blood clotting and bone structure support. It is also a key factor in protein synthesis within the body.

Additional Information

Lab Verified Vegan

Since 1973, we've scoured the globe for the highest quality ingredients, connecting you with the most efficacious supplements that help you live brighter & embrace the moments that matter most.

Store in a cool, dry place.

100% PCR BOTTLES

Product Details

UPC / SKU 0 76280 04212 2

DSLD Entry Date 2025-01-23

Product Type Vitamin

Form Tablet or Pill

Brand Solaray

DSLD ID 326153

Data Updated 2026-04-11

Research Evidence

332 Research Sources

59 Avg Quality Score

220 Meta Analysis

56 Systematic Review

30 Rct

16 Clinical Trial

3 Guideline

3 Regulatory Source

1 Narrative Review

1 Other

1 Openfda Safety

A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI Cochrane

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI

A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2016

PubMed DOI

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI

A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2025

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

Meta Analysis The Cochrane database of systematic reviews 2018

PubMed DOI

A Antiplatelet agents and anticoagulants for hypertension

Systematic Review The Cochrane database of systematic reviews 2022

PubMed DOI

A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Meta Analysis The Cochrane database of systematic reviews 2012

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation